485. Rahnea-Nita R. A., Rebegea L. F., Toma R. V., Mocanu H., Soare I., Mihailov R., Nechifor A., Guliciuc M., Constantin G. B., Rahnea-Nita G. Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastases-Favorable Response after Immunotherapy Continued beyond Progression // J Pers Med. ‒ 2024. ‒ T. 14, № 1.
486. Ferrucci P. F., Di Giacomo A. M., Del Vecchio M., Atkinson V., Schmidt H., Schachter J., Queirolo P., Long G. V., Stephens R., Svane I. M., Lotem M., Abu-Amna M., Gasal E., Ghori R., Diede S. J., Croydon E. S., Ribas A., Ascierto P. A., team K.-i. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma // J Immunother Cancer. ‒ 2020. ‒ T. 8, № 2.
487. Hamid O., Robert C., Daud A., Hodi F. S., Hwu W. J., Kefford R., Wolchok J. D., Hersey P., Joseph R. W., Weber J. S., Dronca R., Gangadhar T. C., Patnaik A., Zarour H., Joshua A. M., Gergich K., Elassaiss-Schaap J., Algazi A., Mateus C., Boasberg P., Tumeh P. C., Chmielowski B., Ebbinghaus S. W., Li X. N., Kang S. P., Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma // N Engl J Med. ‒ 2013. ‒ T. 369, № 2. ‒ C. 134-44.
488. Ugurel S., Hildenbrand R., Zimpfer A., La Rosee P., Paschka P., Sucker A., Keikavoussi P., Becker J. C., Rittgen W., Hochhaus A., Schadendorf D. Lack of clinical efficacy of imatinib in metastatic melanoma // Br J Cancer. ‒ 2005. ‒ T. 92, № 8. ‒ C. 1398-405.
489. Wyman K., Atkins M. B., Prieto V., Eton O., McDermott D. F., Hubbard F., Byrnes C., Sanders K., Sosman J. A. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy // Cancer. ‒ 2006. ‒ T. 106, № 9. ‒ C. 2005-11.
490. D'Angelo S. P., Larkin J., Sosman J. A., Lebbe C., Brady B., Neyns B., Schmidt H., Hassel J. C., Hodi F. S., Lorigan P., Savage K. J., Miller W. H., Jr., Mohr P., Marquez-Rodas I., Charles J., Kaatz M., Sznol M., Weber J. S., Shoushtari A. N., Ruisi M., Jiang J., Wolchok J. D. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis // J Clin Oncol. ‒ 2017. ‒ T. 35, № 2. ‒ C. 226-235.
491. Shoushtari A. N., Munhoz R. R., Kuk D., Ott P. A., Johnson D. B., Tsai K. K., Rapisuwon S., Eroglu Z., Sullivan R. J., Luke J. J., Gangadhar T. C., Salama A. K., Clark V., Burias C., Puzanov I., Atkins M. B., Algazi A. P., Ribas A., Wolchok J. D., Postow M. A. The efficacy of anti-PD-1 agents in acral and mucosal melanoma // Cancer. ‒ 2016. ‒ T. 122, № 21. ‒ C. 3354-3362.
492. Weichenthal M., Ugurel S., Leiter U. M., Satzger I., Kähler K. C., Welzel J., Pföhler C., Feldmann-Böddeker I., Meier F. E., Terheyden P., Haferkamp S., Herbst R., Ulrich J., Utikal J., Kreuter A., Gutzmer R., Schadendorf D., Mohr P. Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry // Journal of Clinical Oncology. ‒ 2019. ‒ T. 37, № 15_suppl. ‒ C. 9505-9505.
493. Weber J. S., Gibney G., Sullivan R. J., Sosman J. A., Slingluff C. L., Jr., Lawrence D. P., Logan T. F., Schuchter L. M., Nair S., Fecher L., Buchbinder E. I., Berghorn E., Ruisi M., Kong G., Jiang J., Horak C., Hodi F. S. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial // Lancet Oncol. ‒ 2016. ‒ T. 17, № 7. ‒ C. 943-55.
494. Reschke R., Ziemer M. Rechallenge with checkpoint inhibitors in metastatic melanoma // J Dtsch Dermatol Ges. ‒ 2020. ‒ T. 18, № 5. ‒ C. 429-436.
495. Wolchok J. D., Hoos A., O'Day S., Weber J. S., Hamid O., Lebbe C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F. S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria // Clin Cancer Res. ‒ 2009. ‒ T. 15, № 23. ‒ C. 7412-20.
496. Nishino M., Giobbie-Hurder A., Gargano M., Suda M., Ramaiya N. H., Hodi F. S. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements // Clin Cancer Res. ‒ 2013. ‒ T. 19, № 14. ‒ C. 3936-43.
497. Seymour L., Bogaerts J., Perrone A., Ford R., Schwartz L. H., Mandrekar S., Lin N. U., Litiere S., Dancey J., Chen A., Hodi F. S., Therasse P., Hoekstra O. S., Shankar L. K., Wolchok J. D., Ballinger M., Caramella C., de Vries E. G. E., group R. w. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics // Lancet Oncol. ‒ 2017. ‒ T. 18, № 3. ‒ C. e143-e152.
498. Martinez S. R., Young S. E. A rational surgical approach to the treatment of distant melanoma metastases // Cancer Treat Rev. ‒ 2008. ‒ T. 34, № 7. ‒ C. 614-20.
499. Sosman J. A., Moon J., Tuthill R. J., Warneke J. A., Vetto J. T., Redman B. G., Liu P. Y., Unger J. M., Flaherty L. E., Sondak V. K. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430 // Cancer. ‒ 2011. ‒ T. 117, № 20. ‒ C. 4740-06.
500. Howard J. H., Thompson J. F., Mozzillo N., Nieweg O. E., Hoekstra H. J., Roses D. F., Sondak V. K., Reintgen D. S., Kashani-Sabet M., Karakousis C. P., Coventry B. J., Kraybill W. G., Smithers B. M., Elashoff R., Stern S. L., Cochran A. J., Faries M. B., Morton D. L. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I) // Ann Surg Oncol. ‒ 2012. ‒ T. 19, № 8. ‒ C. 2547-55.
501. Blankenstein S. E., Aarts M. J. B., van den Berkmortel F., Boers-Sonderen M., van den Eertwegh A. J. M., Franken M. G., de Groot J. W., Haanen J. B. A. G., Hospers G., Kapiteijn E., Piersma D., Van Rijn R., Suijkerbuijk K., ten Tije A. J., Van Der Veldt A. A. M., Vreugdenhil G., Wouters M. W. J. M., van Akkooi A. C. J. Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy // J Clin Oncol ‒2020. ‒ T. 38.